少関節型乾癬性関節炎患者における インターロイキン-17抑制
Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y
Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.
June 2023
April 2023
Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study
Rheumatology (Oxford).2023;kead181. doi 10.1093/rheumatology/kead181.
Results from the 52-week phase 3 EXCEED study showed that secukinumab and adalimumab both display similar efficacy in time to resolution of enthesitis, in patients with PsA, irrespective of baseline enthesitis severity and individual site distribution.
Keywords:
March 2022
乾癬性関節炎患者を対象としたフェーズ３試験におけ るセクキヌマブの患者報告アウトカム
Lancet. 2022. Epub ahead of print
Predefined analysis of FUTURE 5, the largest Phase 3 randomised trial of secukinumab in patients with PsA to date, demonstrates that secukinumab results in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses, compared with placebo.The fully human anti-interleukin 17A monoclonal antibody, secukinumab has shown clinical and radiographical efficacy in patients with PsA, yet the clinical significance of improvements across a wide variety of PROs r...